Archived research. Equity forecasting is part of the Runchey Research archive (methodology era 1) and is no longer actively updated. Everything remains published at its original URL. Browse the archive
Will the FDA convene an Advisory Committee for brepocitinib DM by 2026-09-15?
Current Prediction
Why This Question Matters
An FDA Advisory Committee (AdCom) on brepocitinib DM is a leading indicator within the PDUFA process. If convened, approval probability mechanically drops 5-10% and AdCom vote becomes a proximate catalyst before PDUFA. Most Priority Review NDAs with strong Ph3 data are approved without AdCom (~75% bypass rate for orphan autoimmune). A YES (AdCom convened by 2026-09-15) would signal FDA has specific clinical or label questions requiring external review. Because this resolves before PDUFA and is itself a meaningful binary, it is valuable diagnostic information separate from the PDUFA market.
Prediction Distribution
Individual Predictions(9 runs)
Base rate for AdCom convening in priority-reviewed orphan autoimmune NDAs with clean Ph3 data is ~25-30%, elevated to ~30-35% with JAK class boxed warning considerations. However, no AdCom announcement as of April 22 is a meaningfully negative signal: AdComs are typically announced 60-90 days in advance via Federal Register, and the window from April 22 to September 15 PDUFA is ~5 months. If FDA intended an AdCom, announcement would likely have already occurred. The ~22% reflects residual probability of late-stage AdCom convening for label negotiation, partially discounted for the now-narrow announcement window.
The base rate of 25-30% for priority-reviewed orphan autoimmune AdCom convening applies to the full review period, but AdCom announcements typically come 2-4 months before PDUFA. With PDUFA likely Q3 2026 (target September 2026) and no April 22 announcement, we are already within the typical announcement window for a September PDUFA. ~50% of AdComs for this type of NDA would have been announced by now if they were going to happen. That halves the residual probability from 25-30% to roughly 12-15%. Adding back some tail for late-stage AdCom announcement (unusual but not unprecedented for JAK class) brings us to ~25%.
Decision tree with timing adjustment. P(AdCom at some point during review) ~25-30% baseline. P(announcement by September 15 | AdCom happens) ~85% (AdComs before PDUFA typically announced 45-90 days ahead; if AdCom is happening, announcement by Sept 15 for Q3 PDUFA is near-certain). P(AdCom announced between April 22 and September 15 | AdCom will happen) — we've already passed much of the typical announcement window, so conditional probability of 'announcement between now and Sept 15' given AdCom-happens is reduced. Net ~0.20-0.22.
Base rate 25-30% for priority-reviewed orphan autoimmune AdCom convening, with modest elevation for JAK class label considerations (~30-35%). Partial discount for no April 22 announcement (typical 60-90 day lead time). Conservative estimate: 0.25 reflects baseline AdCom probability with timing discount partially applied.
Slight negative tilt. VALOR Ph3 clean dataset (primary + 9/9 secondary endpoints) and severe unmet need in orphan DM favor FDA approval without external review. JAK class boxed warning is already established class-wide, reducing need for AdCom on this specific product. No April 22 announcement is meaningful. Net 0.22.
Slight positive tilt from JAK class environment post-2023. Rinvoq/Olumiant/Xeljanz safety environment has elevated FDA scrutiny on JAK approvals specifically; brepocitinib's Priority Review does not eliminate this. Base rate 25-30% + JAK class elevation gets toward 30-35%. April 22 absence modestly reduces to 0.28.
Base rate 25-30% with modest JAK class elevation. April 22 absence partial discount. Net 0.25.
Slight negative tilt. Clean VALOR data minimizes clinical questions; JAK boxed warning already class-wide. April 22 absence meaningful. Net 0.22.
Base rate 25-30% adjusted modestly for JAK class and April 22 absence. Net 0.25.
Resolution Criteria
Resolves YES if, by 2026-09-15 (approximately 2 weeks before estimated PDUFA), the FDA announces via FDA.gov, Federal Register, Roivant/Priovant 8-K, or FDA press release that an Advisory Committee meeting will be convened to review the brepocitinib DM NDA. Resolves NO if no AdCom announcement has been made by 2026-09-15, OR if the FDA approves brepocitinib DM before 2026-09-15 without convening AdCom.
Resolution Source
FDA.gov, Federal Register, Roivant/Priovant 8-K filings, FDA press releases
Source Trigger
Brepocitinib DM FDA advisory committee convened
Full multi-lens equity analysis